Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Change in Account Payables: 2016-2025

Historic Change in Account Payables for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to -$3.3 million.

  • Collegium Pharmaceutical's Change in Account Payables rose 44.77% to -$3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year increase of 162.85%. This contributed to the annual value of -$11.3 million for FY2024, which is 322.84% down from last year.
  • According to the latest figures from Q3 2025, Collegium Pharmaceutical's Change in Account Payables is -$3.3 million, which was up 52.85% from -$7.0 million recorded in Q2 2025.
  • Collegium Pharmaceutical's Change in Account Payables' 5-year high stood at $13.9 million during Q1 2025, with a 5-year trough of -$7.0 million in Q2 2025.
  • Its 3-year average for Change in Account Payables is -$231,273, with a median of -$573,000 in 2023.
  • In the last 5 years, Collegium Pharmaceutical's Change in Account Payables tumbled by 1,150.00% in 2021 and then spiked by 648.86% in 2025.
  • Quarterly analysis of 5 years shows Collegium Pharmaceutical's Change in Account Payables stood at -$3.5 million in 2021, then fell by 17.00% to -$4.1 million in 2022, then spiked by 219.60% to $5.0 million in 2023, then plummeted by 83.65% to $810,000 in 2024, then surged by 44.77% to -$3.3 million in 2025.
  • Its Change in Account Payables stands at -$3.3 million for Q3 2025, versus -$7.0 million for Q2 2025 and $13.9 million for Q1 2025.